Ziresovir
Appearance
From Wikipedia, the free encyclopedia
Medication
Pharmaceutical compound
| Clinical data | |
|---|---|
| Trade names | Ziresovir |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H25N5O3S |
| Molar mass | 439.53g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.[1] [2] [3]
See also
[edit ]References
[edit ]- ↑ Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, et al. (July 2019). "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry. 62 (13): 6003–6014. doi:10.1021/acs.jmedchem.9b00654 . PMID 31194544.
- ↑ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.201904006. PMC 7132446 . PMID 30974127.
- ↑ Taylor, Nick Paul (7 April 2022). "ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data". Fierce Biotech. Retrieved 17 July 2022.
Stub icon
This antiinfective drug article is a stub. You can help Wikipedia by adding missing information.